Loss of asthma control after cessation of omalizumab treatment: real life data.

Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations. Lung India (2015) 1.07

Omalizumab in an allergology clinic: real life experience and future developments. Postepy Dermatol Alergol (2014) 0.93

Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study. BMC Pulm Med (2016) 0.76

Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: a case series from Poland. Arch Med Sci (2015) 0.76

Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience. BMC Pulm Med (2016) 0.75

Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential. Ther Adv Chronic Dis (2016) 0.75

Omalizumab in the prevention of anaphylaxis during immunotherapy: a case report. Postepy Dermatol Alergol (2014) 0.75

Effectiveness of omalizumab in an asthmatic patient with severe airway and blood eosinophilia. Postepy Dermatol Alergol (2015) 0.75

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy (2005) 3.22

Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol (2004) 2.42

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol (2009) 1.92

After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy (2009) 1.74

Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy (2005) 1.35

Reduction of asthma burden is possible through National Asthma Plans. Allergy (2010) 1.21

Therapeutic options for severe asthma. Arch Med Sci (2012) 1.11

Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. Respir Med (2014) 0.99

An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy (2008) 0.95

Asthma: beyond corticosteroid treatment. Arch Med Sci (2013) 0.95

[The analysis of the factors influencing the development of glucocorticoid resistance in the etiopathogenesis of severe bronchial asthma]. Postepy Biochem (2010) 0.88

Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up. Ther Adv Respir Dis (2012) 0.88

Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. J Allergy Clin Immunol (2008) 0.86

[Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications]. Pneumonol Alergol Pol (2009) 0.84

[Epidemics of allergic diseases: a new health problem in the modern world]. Pol Merkur Lekarski (2003) 0.80